Study of ASN51 in Adults With Early Alzheimer's Disease

Summary

The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of multiple doses of ASN51 in adult participants with early Alzheimer's disease (AD).

Timeline

Start

2024-10-16

Primary completion

2024-11-08

Completion

2024-11-08

Drugs

Indications